VistaGen Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- VistaGen Therapeutics, Inc. Vistagen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience-based therapies via nose-to-brain neurocircuitry, develops and seeks to commercialize intranasal pherine product candidates for neuropsychiatric and neurological disorders. The company's diversified pipeline features fasedienol (PH94B), an investigational pherine nasal spray in Phase 3 PALISADE-3 and PALISADE-4 trials for acute treatment of anxiety in adults with social anxiety disorder; itruvone (PH10), an odorless synthetic investigational neuroactive pherine nasal spray in Phase 2 trials for major depressive disorder; PH80, an investigational pherine nasal spray in Phase 2 for vasomotor symptoms including menopausal hot flashes and premenstrual dysphoric disorder; PH15, an investigational pherine nasal spray in Phase 2 for cognitive impairment due to mental fatigue; PH284, an investigational pherine nasal spray in Phase 2 for loss of appetite and cachexia associated with chronic disorders such as cancer or heart disease; and AV-101, an oral NMDA receptor prodrug targeting depression, suicidal ideation, and neuropathic pain. Founded in 1998 and headquartered in South San Francisco, California, VistaGen Therapeutics operates primarily in the United States with a focus on patients suffering from psychiatric conditions including social anxiety disorder, depression, and women's health disorders related to menopause. Recent developments include completion of the randomized portion of the PALISADE-3 Phase 3 trial with topline results expected in Q4 2025 and PALISADE-4 topline results anticipated in H1 2026; appointment of Paul Edick, former CEO of Xeris Pharmaceuticals, to the Board of Directors in October 2025; appointment of Elissa Cote as Chief Corporate Development Officer; presentation of new PH80 data at The Menopause Society 2025 Annual Meeting; fiscal 2026 Q2 results showing $77.2 million in cash equivalents as of September 30, 2025 amid increased R&D spending of $15.9 million; and ongoing open-label extension in PALISADE-3 allowing fasedienol use for up to 12 months.
Company News
2 Falling Stocks Call Traders Are Targeting Today
Vistagen Reports Positive Findings Supporting Fasedienol's Potential in Very Severe Social Anxiety Disorder
Penny Stock Vistagen Analyst Highlights Caution after Anxiety Data
Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen to Present at Psych Congress 2026
Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN)
Vistagen Appoints Douglas J. Williamson to its Board of Directors
Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
Vistagen to Participate in Jefferies 2026 Global Healthcare Conference
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder